We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hemorrhagic Fever Viruses Could Be Bioweapons

By Biotechdaily staff writers
Posted on 27 May 2002
Hemorrhagic fever viruses such as Ebola, Marburg, and Lassa could be used as biologic weapons, according to a report from a panel of experts convened by the Center for Civilian Biodefense Strategies at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA). More...
The panel's consensus statement was published in the May 8, 2002, issue of the Journal of the American Medical Association (JAMA).

Hemorrhagic fever viruses are considered "Category A” biologic weapons agents by the US Centers for Disease Control and Prevention (CDC) because they have the potential to cause widespread illness and death. The panel's report focused on eight viruses: Ebola, Marburg, Lassa fever, New World Arenavirus, Rift Valley fever, yellow fever, Ornsk hemorrhagic fever, and Kyasanur Forest disease. Ebola and Marburg are among the most deadly of these. Ebola kills 50-90% of those infected, and Marburg is fatal in 23-70% of cases.

There are no widely available diagnostic tests for these viruses, and few effective therapies or vaccines are available to treat them. The panel says strict infection controls need to be used during an outbreak, since many of the viruses can be spread by person-to-person contact. Patients should be isolated, and clinicians should wear protective gear.

"The Working Group's consensus recommends improvement to our diagnostic capacity and the development of a rapid test for diagnosing hemorrhagic fever viruses,” said Luciana Borio, M.D., lead author and a fellow at the Hopkins Center for Civilian Biodefense Strategies. "Research efforts should also focus on new antiviral medications, vaccines, and a more fundamental scientific study of the viruses that cause hemorrhagic illness.”




Related Links:
Center for Civilian Biodefense
JAMA

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automated Urinalysis Solution
UN-9000
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.